ANTXNMSHealthcare·Biotechnology#356 in industry

AN2 Therapeutics, Inc.

+298.3% · 90d

$4.80

+0.46 (+10.60%)

After-Hours $4.80(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

The summary provided only contains a request for the filing content and does not include the SEC filing details for ANTX. Please upload the actual ARS document for a headline

ANTXAN2 Therapeutics, Inc.

⚠️ Analysis Blocked 🛑 I am ready to act as your expert financial analyst and educator! I understand the highly detailed structure, the conversational tone, and the requirement to surface every material detail while translating complex SEC filings into simple, actionable insights. **However, the a

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

ANTX Sets June 3 Shareholder Meeting to Elect Directors, Ratify Auditor

ANTXAN2 Therapeutics, Inc.

# 🧾 What This Document Is This is a **proxy statement (DEF 14A)** for AN2 Therapeutics. Think of it as the official "agenda packet" for the company's annual shareholder meeting. Its job is to give you all the information you need to vote on key decisions, even if you can't attend in person. * **

Read summaryView on SEC EDGAR

Key Data

Market Cap$172.8M

Open$4.32

Prev Close$4.34

Day Range$4.32 – $5.10

52W Range$1.00 – $6.91

Volume618,169

P/E (TTM)—

EPS$-1.16

Dividend Yield—

Beta-1.32

Price Target$1.00(-79.2%)

Analyst Ratings

Hold1 analysts

Buy 0Hold 1Sell 0

About

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Healthcare · Biotechnology

21 employees

www.an2therapeutics.com